Urology Product Preview: Testosterone agent meets efficacy endpoint in phase III studies
August 11th 2014Drugs and devices in the pipeline form Clarus Therapeutics, Nymox Pharmaceutical, Bioniche Life Sciences, Repros Therapeutics, BioLight Life Sciences Investments/Micromedic Technologies, Cubist Pharmaceuticals, Takeda Pharmaceutical, H. Lundbeck A/S, Transplant Genomics, Orion, Bayer, and Roche.
Upfront chemo plus ADT dramatically improves survival
July 24th 2014A new study showing a survival benefit of more than 1 year with a chemotherapy-hormonal therapy combination given prior to castration resistance is being hailed by a leading prostate cancer expert as possibly representing a “new standard” in care.
Diagnosing docs strongly influence PCa Tx decisions
July 21st 2014Diagnosing physicians-urologists in particular-significantly influence decision making in men with low-risk prostate cancer as well as the type of treatment selected, according to researchers from The University of Texas MD Anderson Cancer Center in Houston.
Robotic RP associated with improved margin status
July 7th 2014Robot-assisted radical prostatectomy may be associated with improved surgical margin status compared to open radical prostatectomy for men with intermediate-risk and high-risk prostate cancer, according to a study presented at the AUA annual meeting in Orlando, FL.
Prostate EBRT linked with risk of two other cancers
June 30th 2014Men with prostate cancer who are treated with external beam radiation therapy are at an increased risk for cancer of the bladder and rectum 10 years or more after their prostate cancer diagnosis, according to an analysis using data from the Surveillance, Epidemiology, and End Results program.
Clinicians say active surveillance is effective but rarely recommend it
June 30th 2014The majority of urologists and radiation oncologists feel active surveillance is an effective and underused modality for managing low-risk prostate cancer; however, few of these specialists would recommend this strategy to patients, according to recent survey results.
CCP score strong predictor of localized PCa outcomes
June 16th 2014Results of a validation study confirm that cell cycle progression score provided by a commercially available genomic test (Prolaris) is a strong and independent outcome predictor in men with conservatively managed, clinically localized prostate cancer.
Androgen deprivation therapy overuse still problematic among some urologists
June 9th 2014Inappropriate use of a gonadotropin-releasing hormone agonist for androgen deprivation therapy of localized prostate cancer fell dramatically following implementation of reimbursement cuts mandated by the Medicare Modernization Act of 2003, but overuse remains problematic, according to research presented at the American Society of Clinical Oncology annual meeting in Chicago.
Early chemo-ADT combination may be new PCa standard
June 2nd 2014A new study showing a survival benefit of more than 1 year with a chemotherapy-hormonal therapy combination given prior to castration resistance is being hailed by the study’s first author as a “new standard” of treatment for certain men with metastatic, hormone-sensitive prostate cancer.
Prostate ‘hoax’ book contains no conspiracy theories
May 30th 2014Dr. Henry Rosevear’s blog post about my recently published book, “The Great Prostate Hoax: How big medicine hijacked the PSA test and caused a public health disaster,” does a disservice to the readership of the Urology Times by mischaracterizing the book’s central message.